<p>Taysha Gene Therapies（TSHA）在与 Astellas 的协议到期后重新获得了其针对 Rett 综合症的 TSHA-102 基因治疗项目的全部权利。这一变化在治疗获得 FDA 突破性疗法地位的同时，恢复了他们的战略灵活性。</p>
<p>查看我们对 Taysha Gene Therapies 的最新分析。</p>
<p>在一系列积极的临床消息和对其主要项目的完全控制权回归之后，Taysha Gene Therapies 的股价飙升，过去一个月上涨了 62.8%，年初至今上涨了 155%。尽管本周出现小幅回调，但该股的 1 年总股东回报率仍为 129%，标志着强劲的势头，投资者在关键试验里程碑临近时密切关注。</p>
<p>如果生物技术突破的势头引起了你的关注，考虑一下下一个发现机会：查看完整列表，免费获取。</p>
<p>随着股价已经大幅上涨，分析师们提高了他们的预测，关键问题是 Taysha 的股票是否仍被低估，或者市场是否已经将公司的预期增长计入其中。</p>
<h2>最受欢迎的叙述：低估 50.3%</h2>
<p>Taysha Gene Therapies 最受关注的叙述为其分配的公允价值是其最后收盘价 4.72 美元的两倍多。这使得该股票相对于预期前景显得大幅折扣。</p>
<blockquote>
<p><em>分析师们对 Taysha Gene Therapies 的共识目标价为 6.55 美元，基于他们对未来盈利增长、利润率和其他风险因素的预期。然而，分析师之间存在一定程度的分歧，最乐观的分析师报告的目标价为 8.0 美元，而最悲观的分析师报告的目标价仅为 5.0 美元。</em></p>
</blockquote>
<p>阅读完整叙述。</p>
<p>好奇他们是如何得出如此大胆的估值的？秘密在于雄心勃勃的增长预测和在早期生物技术中罕见的利润前景。想看看哪些关键数字真正推动了这一叙述，以及它们是否经得起审查？深入挖掘，揭示这一定价背后的完整故事。</p>
<p><strong>结果：公允价值为 9.50 美元（被低估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，仍然存在一些关键风险，包括获得及时监管批准的挑战和持续的亏损，这可能会改变 Taysha 的发展轨迹。</p>
<p>了解 Taysha Gene Therapies 叙述中的关键风险。</p>
<h2>构建你自己的 Taysha Gene Therapies 叙述</h2>
<p>对共识不信服或想要得出自己的结论？深入数据，快速制定个人估值。按照你的方式进行。</p>
<p>进行 Taysha Gene Therapies 研究的一个很好的起点是我们的分析，强调了 3 个关键收益和 4 个可能影响你投资决策的重要警示信号。</p>
<h2>寻找更多投资想法？</h2>
<p>通过筛选大多数投资者忽视的机会，走在众人之前。明天的赢家在等待，不要让他们在其他人犹豫时溜走。</p>
<ul>
<li>当你查看这些 18 只收益率超过 3% 的股息股票时，捕捉稳定的收入流，提供强劲的派息历史。</li>
<li>通过查看这 24 只正在通过先进的人工智能创新塑造未来的 AI 便士股票，发现未开发的增长潜力。</li>
<li>通过搜索这些 878 只基于现金流分析而交易低于其真实价值的被低估股票，揭示隐藏的价值。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也不考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

TSHA

<p>Taysha Gene Therapies (TSHA) 恢复了其针对 Rett 综合症的 TSHA-102 基因疗法的全部权利，并获得了 FDA 突破性疗法地位。该股票在过去一个月上涨了 62.8%，年初至今上涨了 155%，一年期的股东总回报率为 129%。分析师的共识目标价为 6.55 美元，有些人预测高达 8.0 美元。公允价值估计为 9.50 美元，表明该股票被低估，但风险包括监管批准挑战和持续的亏损</p>

<p>Taysha Gene Therapies (TSHA) regained full rights to its TSHA-102 gene therapy program for Rett syndrome after the expiration of an agreement with Astellas. This change restores their strategic flexibility at the same time the therapy received FDA Breakthrough Therapy status.</p>
<div class="lb-trans"><p>Taysha Gene Therapies（TSHA）在与 Astellas 的协议到期后重新获得了其针对 Rett 综合症的 TSHA-102 基因治疗项目的全部权利。这一变化在治疗获得 FDA 突破性疗法地位的同时，恢复了他们的战略灵活性。</p>
</div><p>See our latest analysis for Taysha Gene Therapies.</p>
<div class="lb-trans"><p>查看我们对 Taysha Gene Therapies 的最新分析。</p>
</div><p>Following a wave of positive clinical news and the return of full control over its lead program, Taysha Gene Therapies’ share price has surged, rising 62.8% in the past month and 155% year-to-date. Despite a small pullback this week, the stock’s 1-year total shareholder return stands at 129%, marking strong momentum that investors are watching closely as pivotal trial milestones approach.</p>
<div class="lb-trans"><p>在一系列积极的临床消息和对其主要项目的完全控制权回归之后，Taysha Gene Therapies 的股价飙升，过去一个月上涨了 62.8%，年初至今上涨了 155%。尽管本周出现小幅回调，但该股的 1 年总股东回报率仍为 129%，标志着强劲的势头，投资者在关键试验里程碑临近时密切关注。</p>
</div><p>If momentum in biotech breakthroughs has your attention, consider the next discovery opportunity: See the full list for free.</p>
<div class="lb-trans"><p>如果生物技术突破的势头引起了你的关注，考虑一下下一个发现机会：查看完整列表，免费获取。</p>
</div><p>With the stock already up sharply and analysts raising their forecasts, the key question now is whether Taysha shares are still undervalued or if the market has already priced in the company’s anticipated growth.</p>
<div class="lb-trans"><p>随着股价已经大幅上涨，分析师们提高了他们的预测，关键问题是 Taysha 的股票是否仍被低估，或者市场是否已经将公司的预期增长计入其中。</p>
</div><h2>Most Popular Narrative: 50.3% Undervalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：低估 50.3%</h2>
</div><p>Taysha Gene Therapies' most followed narrative assigns a fair value that is more than double its last close price of $4.72. This makes the stock appear deeply discounted relative to the projected outlook.</p>
<div class="lb-trans"><p>Taysha Gene Therapies 最受关注的叙述为其分配的公允价值是其最后收盘价 4.72 美元的两倍多。这使得该股票相对于预期前景显得大幅折扣。</p>
</div><blockquote>
<p><em>The analysts have a consensus price target of $6.55 for Taysha Gene Therapies based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $8.0 and the most bearish reporting a price target of just $5.0.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>分析师们对 Taysha Gene Therapies 的共识目标价为 6.55 美元，基于他们对未来盈利增长、利润率和其他风险因素的预期。然而，分析师之间存在一定程度的分歧，最乐观的分析师报告的目标价为 8.0 美元，而最悲观的分析师报告的目标价仅为 5.0 美元。</em></p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>阅读完整叙述。</p>
</div><p>Curious how they arrived at such a bold valuation for Taysha? The secret lies in ambitious growth forecasts and a profit outlook rarely seen in early-stage biotech. Want to see which key numbers truly drive this narrative and if they hold up to scrutiny? Push below the surface to uncover the full story behind this pricing.</p>
<div class="lb-trans"><p>好奇他们是如何得出如此大胆的估值的？秘密在于雄心勃勃的增长预测和在早期生物技术中罕见的利润前景。想看看哪些关键数字真正推动了这一叙述，以及它们是否经得起审查？深入挖掘，揭示这一定价背后的完整故事。</p>
</div><p><strong>Result: Fair Value of $9.50 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为 9.50 美元（被低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, there are still key risks, including the challenge of gaining timely regulatory approval and the ongoing unprofitability, that could alter Taysha's trajectory.</p>
<div class="lb-trans"><p>然而，仍然存在一些关键风险，包括获得及时监管批准的挑战和持续的亏损，这可能会改变 Taysha 的发展轨迹。</p>
</div><p>Find out about the key risks to this Taysha Gene Therapies narrative.</p>
<div class="lb-trans"><p>了解 Taysha Gene Therapies 叙述中的关键风险。</p>
</div><h2>Build Your Own Taysha Gene Therapies Narrative</h2>
<div class="lb-trans"><h2>构建你自己的 Taysha Gene Therapies 叙述</h2>
</div><p>Not convinced by the consensus or want to reach your own conclusions? Dive into the data and craft your personal valuation in just a few minutes. Do it your way.</p>
<div class="lb-trans"><p>对共识不信服或想要得出自己的结论？深入数据，快速制定个人估值。按照你的方式进行。</p>
</div><p>A great starting point for your Taysha Gene Therapies research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.</p>
<div class="lb-trans"><p>进行 Taysha Gene Therapies 研究的一个很好的起点是我们的分析，强调了 3 个关键收益和 4 个可能影响你投资决策的重要警示信号。</p>
</div><h2>Looking for More Investment Ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>Step ahead of the crowd by screening for opportunities most investors overlook. Tomorrow’s winners are waiting, so don’t let them slip by while others hesitate.</p>
<div class="lb-trans"><p>通过筛选大多数投资者忽视的机会，走在众人之前。明天的赢家在等待，不要让他们在其他人犹豫时溜走。</p>
</div><ul>
<li>Capture steady income streams when you check out these 18 dividend stocks with yields &gt; 3% offering yields above 3% and strong payout histories.</li>
<li>Spot untapped growth potential by checking these 24 AI penny stocks that are shaping the future with advanced artificial intelligence innovations.</li>
<li>Uncover hidden value by searching these 878 undervalued stocks based on cash flows that trade below their true worth based on cash flow analysis.</li>
</ul>
<div class="lb-trans"><ul>
<li>当你查看这些 18 只收益率超过 3% 的股息股票时，捕捉稳定的收入流，提供强劲的派息历史。</li>
<li>通过查看这 24 只正在通过先进的人工智能创新塑造未来的 AI 便士股票，发现未开发的增长潜力。</li>
<li>通过搜索这些 878 只基于现金流分析而交易低于其真实价值的被低估股票，揭示隐藏的价值。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也不考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

Taysha Gene Therapies (TSHA)：在重新获得 TSHA-102 权利和获得 FDA 突破性地位后的估值视角